

Carsten M¹/₄ller-Tidow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5825390/publications.pdf>

Version: 2024-02-01

506
papers

20,231
citations

14655

66
h-index

17105

122
g-index

516
all docs

516
docs citations

516
times ranked

27194
citing authors

#	ARTICLE	IF	CITATIONS
1	MALAT-1, a novel noncoding RNA, and thymosin β 4 predict metastasis and survival in early-stage non-small cell lung cancer. <i>Oncogene</i> , 2003, 22, 8031-8041.	5.9	1,986
2	Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. <i>Nature Medicine</i> , 2012, 18, 605-611.	30.7	584
3	The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1984-1992.	1.1	515
4	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. <i>Blood</i> , 2012, 119, 1501-1510.	1.4	359
5	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	10.7	347
6	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. <i>Cancer Cell</i> , 2015, 27, 658-670.	16.8	341
7	Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 61-69.	1.6	315
8	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. <i>Lancet</i> , The, 2010, 376, 2000-2008.	13.7	290
9	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3110-3118.	1.6	290
10	Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells. <i>Molecular and Cellular Biology</i> , 2004, 24, 2890-2904.	2.3	280
11	Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes. <i>Molecular Cell</i> , 2009, 36, 326-339.	9.7	278
12	Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. <i>Blood</i> , 2003, 101, 3164-3173.	1.4	274
13	Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. <i>Blood</i> , 2010, 115, 1768-1778.	1.4	265
14	EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5324-5329.	7.1	260
15	The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. <i>Nature Medicine</i> , 2002, 8, 743-750.	30.7	258
16	Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1160-1168.	2.4	257
17	AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. <i>Blood</i> , 2005, 106, 265-273.	1.4	224
18	Constitutive Activation of Akt by Flt3 Internal Tandem Duplications Is Necessary for Increased Survival, Proliferation, and Myeloid Transformation. <i>Cancer Research</i> , 2005, 65, 9643-9650.	0.9	205

#	ARTICLE	IF	CITATIONS
19	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood</i> , 2014, 124, 1426-1433.	1.4	204
20	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. <i>PLoS ONE</i> , 2015, 10, e0136023.	2.5	202
21	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 69-78.	30.7	192
22	The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6478-6483.	7.1	189
23	Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 1302-1310.	7.2	181
24	Flt3-dependent transformation by inactivating c-Cbl mutations in AML. <i>Blood</i> , 2007, 110, 1004-1012.	1.4	177
25	Activation mechanisms of STAT5 by oncogenic Flt3-ITD. <i>Blood</i> , 2007, 110, 370-374.	1.4	170
26	S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2004, 64, 5564-5569.	0.9	169
27	AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. <i>Nature Cell Biology</i> , 2017, 19, 844-855.	10.3	132
28	Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2005, 65, 1778-1782.	0.9	124
29	NF- κ B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 535-547.	7.2	120
30	C/EBP β regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. <i>Blood</i> , 2010, 116, 5638-5649.	1.4	119
31	Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer. <i>Journal of Biological Chemistry</i> , 2001, 276, 47709-47714.	3.4	118
32	Alarmins MRP8 and MRP14 Induce Stress Tolerance in Phagocytes under Sterile Inflammatory Conditions. <i>Cell Reports</i> , 2014, 9, 2112-2123.	6.4	118
33	Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 2882-2890.	1.4	116
34	The C/EBP β tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. <i>Blood</i> , 2007, 109, 3895-3905.	1.4	115
35	Origins of aberrant DNA methylation in acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 1-14.	7.2	112
36	STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors. <i>Molecular Cancer Research</i> , 2012, 10, 52-65.	3.4	109

#	ARTICLE	IF	CITATIONS
37	High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets. <i>Clinical Cancer Research</i> , 2004, 10, 1241-1249.	7.0	107
38	The Cyclin A1-CDK2 Complex Regulates DNA Double-Strand Break Repair. <i>Molecular and Cellular Biology</i> , 2004, 24, 8917-8928.	2.3	106
39	The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. <i>Leukemia</i> , 2007, 21, 1638-1647.	7.2	101
40	Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. <i>Blood</i> , 2005, 105, 3699-3706.	1.4	99
41	S100A2 Induces Metastasis in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 22-29.	7.0	99
42	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. <i>Blood</i> , 2021, 138, 318-330.	1.4	98
43	Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1383-1394.	7.0	95
44	Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. <i>Nature Cell Biology</i> , 2020, 22, 896-906.	10.3	93
45	Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. <i>Blood</i> , 2010, 116, 3564-3571.	1.4	90
46	DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2007, 67, 1370-1377.	0.9	89
47	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2017, 31, 549-562.e11.	16.8	89
48	Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 288-296.	1.6	88
49	BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. <i>Blood</i> , 2010, 115, 3185-3195.	1.4	85
50	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	1.4	85
51	Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. <i>Blood</i> , 2016, 127, 1173-1182.	1.4	83
52	Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. <i>Oncogene</i> , 2005, 24, 2739-2744.	5.9	82
53	CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	1.4	82
54	Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). <i>Journal of Clinical Medicine</i> , 2019, 8, 200.	2.4	80

#	ARTICLE	IF	CITATIONS
55	Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1956.	4.8	79
56	Signal Transduction of Oncogenic Flt3. <i>International Journal of Hematology</i> , 2005, 82, 93-99.	1.6	77
57	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. <i>Blood</i> , 2011, 117, 2935-2943.	1.4	76
58	Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use. <i>British Journal of Haematology</i> , 2014, 165, 17-38.	2.5	76
59	Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states. <i>Nature Immunology</i> , 2021, 22, 1577-1589.	14.5	76
60	Epigenetic dysregulation of K _{Ca} 3.1 channels induces poor prognosis in lung cancer. <i>International Journal of Cancer</i> , 2015, 137, 1306-1317.	5.1	75
61	Allogeneic Stem-Cell Transplantation in Patients With <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-410.	1.6	74
62	Chromatin modifications induced by PML-RAR α repress critical targets in leukemogenesis as analyzed by ChIP-Chip. <i>Blood</i> , 2008, 111, 2887-2895.	1.4	73
63	The EPHB6 Receptor Tyrosine Kinase Is a Metastasis Suppressor That Is Frequently Silenced by Promoter DNA Hypermethylation in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2275-2283.	7.0	73
64	Identification of acute myeloid leukaemia associated microRNA expression patterns. <i>British Journal of Haematology</i> , 2008, 140, 153-161.	2.5	72
65	Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. <i>Blood</i> , 2012, 119, 2346-2357.	1.4	72
66	Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. <i>Cell Cycle</i> , 2009, 8, 1991-1996.	2.6	71
67	Inhibition of IRE1 α -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 18736-18749.	1.8	71
68	RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. <i>Blood</i> , 2005, 105, 2107-2114.	1.4	70
69	Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. <i>Nature Communications</i> , 2021, 12, 1366.	12.8	69
70	Expression of SOCS-1, Suppressor of Cytokine Signalling-1, in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2004, 123, 737-745.	0.7	68
71	Characterization of the Ca ²⁺ -regulated Ezrin-S100P Interaction and Its Role in Tumor Cell Migration. <i>Journal of Biological Chemistry</i> , 2008, 283, 29331-29340.	3.4	68
72	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4935-4946.	7.0	68

#	ARTICLE	IF	CITATIONS
73	CBF β -SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia. <i>Cell</i> , 2018, 174, 172-186.e21.	28.9	68
74	Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4333-4338.	1.6	67
75	Idelalisib for optimized CD19 α -specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2019, 145, 1312-1324.	5.1	67
76	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <i>Blood</i> , 2020, 135, 1517-1530.	1.4	67
77	E- and A-type cyclins as markers for cancer diagnosis and prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2003, 3, 617-633.	3.1	66
78	The molecular pathogenesis of acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 195-221.	4.4	63
79	Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression. <i>Neuropsychobiology</i> , 2010, 62, 121-131.	1.9	63
80	Keratinocytes Determine Th1 Immunity during Early Experimental Leishmaniasis. <i>PLoS Pathogens</i> , 2010, 6, e1000871.	4.7	63
81	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 \times 2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 257-270.	1.6	63
82	Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. <i>Blood</i> , 2022, 139, 142-147.	1.4	63
83	C/EBP β mediates nicotinamide-enhanced clearance of <i>Staphylococcus aureus</i> in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 3316-3329.	8.2	62
84	DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. <i>Blood</i> , 2013, 121, 178-187.	1.4	61
85	Wnt signaling regulates transendothelial migration of monocytes. <i>Journal of Leukocyte Biology</i> , 2006, 79, 1306-1313.	3.3	60
86	Identification of Interaction Partners and Substrates of the Cyclin A1-CDK2 Complex. <i>Journal of Biological Chemistry</i> , 2004, 279, 33727-33741.	3.4	59
87	Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression of MALAT-1 lncRNA in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1294-1304.	1.1	59
88	Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. <i>Haematologica</i> , 2011, 96, 972-979.	3.5	58
89	Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. <i>Blood</i> , 2020, 136, 1507-1519.	1.4	57
90	Routine data from hospital information systems can support patient recruitment for clinical studies. <i>Clinical Trials</i> , 2010, 7, 183-189.	1.6	56

#	ARTICLE	IF	CITATIONS
91	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	7.2	56
92	Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. <i>Blood</i> , 2001, 97, 2091-2097.	1.4	55
93	Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. <i>Blood</i> , 2012, 119, 5215-5220.	1.4	54
94	Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 41-52.	1.8	53
95	Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. <i>World Journal of Gastroenterology</i> , 2006, 12, 3297.	3.3	53
96	Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. <i>Nature Communications</i> , 2021, 12, 6960.	12.8	53
97	Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. <i>Blood</i> , 2020, 135, 2059-2070.	1.4	52
98	CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer-binding protein alpha. <i>Blood</i> , 2007, 110, 3695-3705.	1.4	50
99	Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. <i>Nucleic Acids Research</i> , 2008, 36, 5362-5375.	14.5	50
100	DDX41-related myeloid neoplasia. <i>Seminars in Hematology</i> , 2017, 54, 94-97.	3.4	49
101	Chimeric antigen receptor transduced T cells: Tuning up for the next generation. <i>International Journal of Cancer</i> , 2018, 142, 1738-1747.	5.1	49
102	Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2905-2915.	4.1	47
103	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia. <i>Leukemia</i> , 2016, 30, 555-561.	7.2	47
104	Leukemia Gene Atlas – A Public Platform for Integrative Exploration of Genome-Wide Molecular Data. <i>PLoS ONE</i> , 2012, 7, e39148.	2.5	47
105	Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. <i>Leukemia</i> , 2017, 31, 1640-1644.	7.2	46
106	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	2.9	46
107	The Role of Human Equilibrative Nucleoside Transporter 1 on the Cellular Transport of the DNA Methyltransferase Inhibitors 5-Azacytidine and CP-4200 in Human Leukemia Cells. <i>Molecular Pharmacology</i> , 2013, 84, 438-450.	2.3	45
108	DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes. <i>Clinical Cancer Research</i> , 2014, 20, 814-826.	7.0	45

#	ARTICLE	IF	CITATIONS
109	E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. <i>Blood</i> , 2009, 114, 4197-4208.	1.4	44
110	miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. <i>Experimental Hematology</i> , 2011, 39, 1030-1042.e7.	0.4	43
111	CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1070-1076.	2.4	43
112	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1230-1236.	7.2	43
113	The Treatment of Elderly Patients With Acute Myeloid Leukemia. <i>Deutsches Arzteblatt International</i> , 2011, 108, 863-70.	0.9	43
114	Facing the Challenges of Chronic Pruritus: A Report From a Multi-disciplinary Medical Itch Centre in Germany. <i>Acta Dermato-Venereologica</i> , 2015, 95, 266-271.	1.3	42
115	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2021, 148, 419-428.	5.1	42
116	HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 367-378.	4.1	42
117	DNA methylation as a pathogenic event and as a therapeutic target in AML. <i>Cancer Treatment Reviews</i> , 2011, 37, S13-S18.	7.7	41
118	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019, 134, 263-276.	1.4	41
119	Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 123, 413-419.	2.5	40
120	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
121	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	7.2	40
122	Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. <i>Leukemia Research</i> , 2004, 28, 1069-1074.	0.8	39
123	Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I. <i>Leukemia</i> , 2012, 26, 615-622.	7.2	39
124	PML/RAR α -Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. <i>Cancer Research</i> , 2015, 75, 3411-3424.	0.9	39
125	Real-time two- and three-dimensional imaging of monocyte motility and navigation on planar surfaces and in collagen matrices: roles of Rho. <i>Scientific Reports</i> , 2016, 6, 25016.	3.3	39
126	Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. <i>Nature Protocols</i> , 2016, 11, 22-36.	12.0	39

#	ARTICLE	IF	CITATIONS
127	Relapsed/refractory acute myeloid leukemia: any progress?. <i>Current Opinion in Oncology</i> , 2017, 29, 467-473.	2.4	39
128	Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. <i>Cancer Letters</i> , 2003, 190, 89-95.	7.2	38
129	Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. <i>Cell Communication and Signaling</i> , 2012, 10, 19.	6.5	38
130	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. <i>Leukemia</i> , 2016, 30, 1708-1715.	7.2	38
131	Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. <i>Blood</i> , 2016, 127, 1575-1586.	1.4	38
132	Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 8.	17.0	38
133	Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. <i>Haematologica</i> , 2021, 106, 446-453.	3.5	38
134	Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (≥60 years). <i>Bone Marrow Transplantation</i> , 2016, 51, 1441-1448.	2.4	37
135	Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. <i>Molecular Oncology</i> , 2016, 10, 677-692.	4.6	37
136	Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow. <i>Matrix Biology</i> , 2018, 67, 47-62.	3.6	37
137	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. <i>Nature Cancer</i> , 2021, 2, 527-544.	13.2	37
138	Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. <i>Journal of Clinical Virology</i> , 2021, 139, 104847.	3.1	37
139	Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. <i>Annals of Oncology</i> , 2012, 23, 990-996.	1.2	36
140	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the p38-like kinase inhibitor BI-2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 214-222.	2.5	36
141	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLapsE. <i>Leukemia</i> , 2021, 35, 1134-1144.	7.2	36
142	Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. <i>Lung Cancer</i> , 2004, 45, S145-S150.	2.0	35
143	Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. <i>Annals of Oncology</i> , 2008, 19, 1644-1649.	1.2	35
144	Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. <i>Blood</i> , 2006, 107, 2079-2089.	1.4	34

#	ARTICLE	IF	CITATIONS
145	Workflow to improve patient recruitment for clinical trials within hospital information systems – a case-study. <i>Trials</i> , 2008, 9, 2.	1.6	34
146	AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. <i>Blood</i> , 2011, 117, 4328-4337.	1.4	34
147	NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. <i>Oncogene</i> , 2021, 40, 909-921.	5.9	34
148	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soramf Trial. <i>Blood</i> , 2014, 124, 6-6.	1.4	34
149	Transcription factor C/EBP β -induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. <i>Blood</i> , 2013, 122, 2433-2442.	1.4	33
150	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	5.2	33
151	Adjuvant Therapy with Small Hairpin RNA Interference Prevents Non-Small Cell Lung Cancer Metastasis Development in Mice. <i>Cancer Research</i> , 2008, 68, 1896-1904.	0.9	32
152	Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein β from hematopoietic cells in a family with AML. <i>Leukemia</i> , 2011, 25, 1209-1210.	7.2	31
153	Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling. <i>Cellular Signalling</i> , 2012, 24, 2095-2101.	3.6	31
154	The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RAR α and regulates differentiation of hematopoietic cells. <i>Oncogene</i> , 2004, 23, 9162-9172.	5.9	30
155	5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. <i>International Journal of Oncology</i> , 2015, 46, 1192-1204.	3.3	30
156	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. <i>British Journal of Cancer</i> , 2018, 118, 1062-1073.	6.4	30
157	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. <i>Blood</i> , 2018, 132, 1988-1991.	1.4	30
158	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2830-2841.	7.2	30
159	Cell-based immunotherapy approaches for multiple myeloma. <i>British Journal of Cancer</i> , 2019, 120, 38-44.	6.4	30
160	Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients. <i>Blood</i> , 2019, 134, 51-51.	1.4	30
161	Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. <i>Leukemia</i> , 2008, 22, 78-86.	7.2	29
162	Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. <i>Leukemia</i> , 2012, 26, 1030-1037.	7.2	29

#	ARTICLE	IF	CITATIONS
163	Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0164587.	2.5	29
164	Mtss1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia, 2016, 30, 823-832.	7.2	29
165	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica, 2019, 104, 1451-1459.	3.5	29
166	Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Annals of Hematology, 2021, 100, 2087-2093.	1.8	29
167	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	3.5	29
168	CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. Blood, 2021, 138, 1067-1080.	1.4	29
169	Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. Journal of Clinical Investigation, 2020, 130, 2364-2376.	8.2	29
170	Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell, 2022, 29, 760-775.e10.	11.1	29
171	Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma. Clinical Cancer Research, 2009, 15, 520-531.	7.0	28
172	Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leukemia Research, 2011, 35, 620-625.	0.8	28
173	Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients. Molecular Therapy - Methods and Clinical Development, 2020, 17, 448-454.	4.1	28
174	The Inhibitor of Growth Protein 5 (ING5) Depends on INCA1 as a Co-Factor for Its Antiproliferative Effects. PLoS ONE, 2011, 6, e21505.	2.5	27
175	SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood, 2012, 120, 1691-1702.	1.4	27
176	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunology, Immunotherapy, 2019, 68, 1195-1209.	4.2	27
177	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ Open, 2019, 9, e026644.	1.9	27
178	Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia, 2021, 35, 2602-2615.	7.2	27
179	Activation Mechanisms of STAT5 by Oncogenic Flt3-ITD.. Blood, 2006, 108, 1435-1435.	1.4	27
180	Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Molecular Cancer Therapeutics, 2006, 5, 3105-3112.	4.1	26

#	ARTICLE	IF	CITATIONS
181	The Absence of Cutaneous Lymph Nodes Results in a Th2 Response and Increased Susceptibility to <i>Leishmania major</i> Infection in Mice. <i>Infection and Immunity</i> , 2008, 76, 4241-4250.	2.2	26
182	Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1577-1585.	1.3	26
183	Anticancer Therapy by Tumor Vessel Infarction with Polyethylene Glycol Conjugated Retargeted Tissue Factor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2337-2347.	6.4	26
184	Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. <i>Oncology</i> , 2016, 90, 299-306.	1.9	26
185	appreci8: a pipeline for precise variant calling integrating 8 tools. <i>Bioinformatics</i> , 2018, 34, 4205-4212.	4.1	26
186	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. <i>Blood Advances</i> , 2020, 4, 6157-6168.	5.2	26
187	Hematopoietic Sphingosine 1-Phosphate Lyase Deficiency Decreases Atherosclerotic Lesion Development in LDL-Receptor Deficient Mice. <i>PLoS ONE</i> , 2013, 8, e63360.	2.5	26
188	Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia. <i>Leukemia</i> , 2004, 18, 720-726.	7.2	25
189	Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 485-492.	2.4	25
190	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	4.1	25
191	Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia – A Randomised SAL Pilot Study. <i>PLoS ONE</i> , 2012, 7, e52695.	2.5	25
192	Activation of counter-regulatory mechanisms in a rat renal acute rejection model. <i>BMC Genomics</i> , 2008, 9, 71.	2.8	24
193	Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 37-45.	3.0	24
194	Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial. <i>Blood</i> , 2010, 116, 333-333.	1.4	24
195	Cyclin A1 and gametogenesis in fertile and infertile patients: a potential new molecular diagnostic marker. <i>Human Reproduction</i> , 2002, 17, 2338-2343.	0.9	23
196	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1062-1067.	1.3	23
197	MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. <i>Cell Death and Disease</i> , 2018, 9, 814.	6.3	23
198	Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. <i>Cytotherapy</i> , 2019, 21, 566-578.	0.7	23

#	ARTICLE	IF	CITATIONS
199	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 608167.	4.8	23
200	Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0125783.	2.5	23
201	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	7.2	23
202	Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 2059-2070.	2.6	22
203	Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL Bâ€ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, E61-4.	4.1	22
204	The endochondral bone protein <sc>CHM</sc>1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma. <i>Molecular Oncology</i> , 2017, 11, 1288-1301.	4.6	22
205	Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?â€a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2018, 26, 21-32.	2.2	22
206	BCR-ABL + acute myeloid leukemia: are we always dealing with a high-risk disease?. <i>Blood Advances</i> , 2018, 2, 1409-1411.	5.2	22
207	Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. <i>Oncotarget</i> , 2016, 7, 82458-82472.	1.8	22
208	Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development. <i>International Journal of Cancer</i> , 2005, 116, 207-217.	5.1	21
209	Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias. <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 173-180.	2.0	21
210	Emerging Flt3 kinase inhibitors in the treatment of leukaemia. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 153-165.	2.4	21
211	Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells. <i>PLoS ONE</i> , 2012, 7, e40853.	2.5	21
212	Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3â€2-Deoxy-3â€2- ¹⁸ F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 983-988.	5.0	21
213	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	4.8	21
214	Phase I doseâ€escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1018-1021.	2.5	21
215	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	5.2	21
216	Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e44591.	2.5	21

#	ARTICLE	IF	CITATIONS
217	Potential therapeutic impact of CD13 expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0177146.	2.5	21
218	A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. <i>Haematologica</i> , 2012, 97, 1380-1388.	3.5	20
219	Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β 1-integrin-dependent mechanism. <i>International Journal of Cancer</i> , 2016, 138, 964-975.	5.1	20
220	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20
221	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2017, 130, 721-721.	1.4	20
222	MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. <i>Experimental Hematology</i> , 2015, 43, 794-802.e4.	0.4	19
223	An isoform-specific C/EBP β inhibitor targets acute myeloid leukemia cells. <i>Leukemia</i> , 2016, 30, 1612-1615.	7.2	19
224	Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. <i>Human Gene Therapy</i> , 2018, 29, 1167-1182.	2.7	19
225	Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. <i>Nature Genetics</i> , 2021, 53, 1443-1455.	21.4	19
226	Analyses of the genomic methylation status of the human cyclin A1 promoter by a novel real-time PCR-based methodology. <i>FEBS Letters</i> , 2001, 490, 75-78.	2.8	18
227	Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. <i>PLoS ONE</i> , 2017, 12, e0178930.	2.5	18
228	Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1281-1288.	2.0	18
229	Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8448-8453.	7.1	17
230	Inhibitor of Cyclin-dependent Kinase (CDK) Interacting with Cyclin A1 (INCA1) Regulates Proliferation and Is Repressed by Oncogenic Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 28210-28222.	3.4	17
231	Myeloid leukemia with transdifferentiation plasticity developing from T cell progenitors. <i>EMBO Journal</i> , 2016, 35, 2399-2416.	7.8	17
232	Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2018, 36, 789-800.	1.6	17
233	Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2021, 13, 1684.	3.7	17
234	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	5.2	17

#	ARTICLE	IF	CITATIONS
235	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 877477.	4.8	17
236	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	17.0	17
237	Low SMC1A protein expression predicts poor survival in acute myeloid leukemia. <i>Oncology Reports</i> , 2010, 24, 47-56.	2.6	16
238	DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 116.	4.1	16
239	Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. <i>Oncology</i> , 2015, 89, 137-142.	1.9	16
240	miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 36.	6.2	16
241	Shaping of CD56 ^{bri} Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <i>Frontiers in Immunology</i> , 2019, 10, 547.	4.8	16
242	BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. <i>Leukemia</i> , 2020, 34, 1454-1457.	7.2	16
243	A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 828.	1.6	16
244	Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 13-13.	1.4	16
245	Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2011, 118, 1549-1549.	1.4	16
246	Targeted siRNA nanocarrier: a platform technology for cancer treatment. <i>Oncogene</i> , 2022, 41, 2210-2224.	5.9	16
247	Chemotherapy in metastatic malignant triton tumor: Report on two cases. <i>Oncology Reports</i> , 2007, 18, 763-7.	2.6	15
248	HIS-based Kaplan-Meier plots - a single source approach for documenting and reusing routine survival information. <i>BMC Medical Informatics and Decision Making</i> , 2011, 11, 11.	3.0	15
249	Integrative Analyses for Omics Data: A Bayesian Mixture Model to Assess the Concordance of ChIP-chip and ChIP-seq Measurements. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2012, 75, 461-470.	2.3	15
250	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. <i>Annals of Hematology</i> , 2013, 92, 1041-1048.	1.8	15
251	Trabectedin: Supportive care strategies and safety profile. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 279-290.	4.4	15
252	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 840-853.	2.5	15

#	ARTICLE	IF	CITATIONS
253	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020, 105, 161-169.	3.5	15
254	Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. <i>Cancers</i> , 2020, 12, 2322.	3.7	15
255	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. <i>British Journal of Haematology</i> , 2021, 192, 832-842.	2.5	15
256	Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. <i>Haematologica</i> , 2022, 107, 1891-1901.	3.5	15
257	The synthetic furanonaphthoquinone induces growth arrest, apoptosis and differentiation in a variety of leukaemias and multiple myeloma cells. <i>British Journal of Haematology</i> , 2005, 131, 520-529.	2.5	14
258	Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis. <i>Leukemia Research</i> , 2008, 32, 491-494.	0.8	14
259	The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. <i>Oncolmmunology</i> , 2018, 7, e1486356.	4.6	14
260	IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1695-1707.	4.2	14
261	Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma. <i>ESC Heart Failure</i> , 2019, 6, 824-829.	3.1	14
262	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2469.	4.1	14
263	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	3.5	14
264	C/EBP β is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. <i>Oncogene</i> , 2021, 40, 4746-4758.	5.9	14
265	Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 254-254.	1.4	14
266	The Indications for Allogeneic Stem Cell Transplantation in Myeloid Malignancies. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 262-70.	0.9	14
267	Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer. <i>Anticancer Research</i> , 2009, 29, 1157-62.	1.1	14
268	CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2022, 14, e14990.	6.9	14
269	Proteomic analysis of acute promyelocytic leukemia: PML-RAR α leads to decreased phosphorylation of OP18 at serine 63. <i>Proteomics</i> , 2006, 6, 5705-5719.	2.2	13
270	DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cells. <i>International Journal of Cancer</i> , 2007, 121, 706-713.	5.1	13

#	ARTICLE	IF	CITATIONS
271	ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase Signaling. PLoS ONE, 2013, 8, e52872.	2.5	13
272	Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia, 2016, 30, 1781-1784.	7.2	13
273	Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. Cytometry Part B - Clinical Cytometry, 2018, 94, 767-776.	1.5	13
274	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. Cancers, 2020, 12, 2820.	3.7	13
275	CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease. Transplantation, 2020, 104, 2354-2359.	1.0	13
276	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers, 2020, 12, 2704.	3.7	13
277	<sc>Daratumumab, lenalidomide, and dexamethasone</sc> in systemic <sc>lightâ€chain</sc> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American Journal of Hematology, 2021, 96, E253-E257.	4.1	13
278	Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine. Blood, 2010, 116, 3316-3316.	1.4	13
279	ABR, a novel inducer of transcription factor C/EBPÎ±, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. Oncotarget, 2017, 8, 103626-103639.	1.8	13
280	Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR. Cells, 2021, 10, 3208.	4.1	13
281	<sc>CD33</sc>â€directed immunotherapy with thirdâ€generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and <sc>CD33</sc>â€edited acute myeloid leukemia and hematopoietic stem and progenitor cells. International Journal of Cancer, 2022, 150, 1141-1155.	5.1	13
282	Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. British Journal of Cancer, 2001, 85, 1168-1174.	6.4	12
283	Pim2 cooperates with PML-RARÎ± to induce acute myeloid leukemia in a bone marrow transplantation model. Blood, 2010, 115, 4507-4516.	1.4	12
284	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19â€positive malignancies. Oncology Reports, 2021, 46, .	2.6	12
285	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS ONE, 2016, 11, e0160871.	2.5	12
286	Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2022, 101, 681-691.	1.8	12
287	Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia. International Journal of Hematology, 2008, 88, 174-180.	1.6	11
288	Evaluating oligonucleotide properties for DNA microarray probe design. Nucleic Acids Research, 2010, 38, e121-e121.	14.5	11

#	ARTICLE	IF	CITATIONS
289	Proteinase-Activated Receptor 1 (PAR1) Regulates Leukemic Stem Cell Functions. PLoS ONE, 2014, 9, e94993.	2.5	11
290	Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation. Transplant Infectious Disease, 2014, 16, 988-992.	1.7	11
291	Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor. Journal of Ultrasound in Medicine, 2015, 34, 1227-1236.	1.7	11
292	Therapy of older persons with acute myeloid leukaemia. Leukemia Research, 2017, 60, 1-10.	0.8	11
293	Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. Blood, 2017, 129, 319-323.	1.4	11
294	Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. EBioMedicine, 2019, 49, 202-212.	6.1	11
295	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. British Journal of Haematology, 2021, 195, 230-243.	2.5	11
296	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers, 2021, 13, 4706.	3.7	11
297	Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse. Blood, 2018, 132, 253-253.	1.4	11
298	Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells. Blood, 2020, 136, 33-34.	1.4	11
299	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. Blood, 2016, 128, 589-589.	1.4	11
300	A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0164499.	2.5	11
301	Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. PLoS ONE, 2017, 12, e0169921.	2.5	11
302	Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease. Cell Reports Medicine, 2021, 2, 100409.	6.5	11
303	Ageing and interferon gamma response drive the phenotype of neutrophils in the inflamed joint. Annals of the Rheumatic Diseases, 2022, 81, 805-814.	0.9	11
304	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. Blood Advances, 2022, 6, 3294-3303.	5.2	11
305	Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta Haematologica, 2017, 137, 163-172.	1.4	10
306	Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients. Arthritis Research and Therapy, 2018, 20, 278.	3.5	10

#	ARTICLE	IF	CITATIONS
307	Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). <i>Annals of Hematology</i> , 2019, 98, 1393-1401.	1.8	10
308	What's new in consolidation therapy in AML?. <i>Seminars in Hematology</i> , 2019, 56, 96-101.	3.4	10
309	B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.	5.1	10
310	The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. <i>International Journal of Cancer</i> , 2021, 148, 150-160.	5.1	10
311	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 670088.	4.8	10
312	Early bilirubinemia after allogeneic stem cell transplantation – an endothelial complication. <i>Bone Marrow Transplantation</i> , 2021, 56, 1573-1583.	2.4	10
313	Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment. <i>Blood</i> , 2012, 120, 411-411.	1.4	10
314	Ft3 Internal Tandem Duplications Cooperate with Wnt Signaling in Leukemic Signal Transduction.. <i>Blood</i> , 2004, 104, 822-822.	1.4	10
315	Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. <i>PLoS ONE</i> , 2022, 17, e0264407.	2.5	10
316	Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation. <i>Intensive Care Medicine</i> , 2022, 48, 753-755.	8.2	10
317	Analysis of the genetic interactions between Cyclin A1, Atm and p53 during spermatogenesis. <i>Asian Journal of Andrology</i> , 2007, 9, 739-750.	1.6	9
318	The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma. <i>International Journal of Oncology</i> , 2009, 35, 175-9.	3.3	9
319	Neuropharmacology and Management of Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer. <i>Breast Care</i> , 2014, 9, 246-253.	1.4	9
320	Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0158599.	2.5	9
321	Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. <i>Haematologica</i> , 2019, 104, e304-e306.	3.5	9
322	An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. <i>Blood Advances</i> , 2021, 5, 5060-5071.	5.2	9
323	Hematological Malignancies in Adults With a Family Predisposition. <i>Deutsches Arzteblatt International</i> , 2018, 115, 848-854.	0.9	9
324	Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 173-80.	2.0	9

#	ARTICLE	IF	CITATIONS
325	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. <i>Vaccines</i> , 2022, 10, 330.	4.4	9
326	Splenic Marginal Zone Lymphoma: Transformation to Diffuse Large B-Cell Lymphoma With Isolated Cerebral Manifestation. <i>Journal of Clinical Oncology</i> , 2008, 26, 4509-4511.	1.6	8
327	Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. <i>Annals of Hematology</i> , 2009, 88, 1037-1038.	1.8	8
328	Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 382-390.	2.0	8
329	Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 876.e1-876.e11.	1.2	8
330	Acquisition and Transmission of Carbapenemase-Producing (<i>bla</i> KPC-2) <i>Enterobacter cloacae</i> in a Highly Frequented Outpatient Clinic. <i>Clinical Infectious Diseases</i> , 2021, 72, e158-e161.	5.8	8
331	Constitutive Activation of Akt and mTOR by Flt3 Internal Tandem Duplications Mediates Myeloid Leukemogenesis and Can Be Inhibited by Rapamycin. <i>Blood</i> , 2004, 104, 2532-2532.	1.4	8
332	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008, 112, 2973-2973.	1.4	8
333	Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review). <i>Oncology Reports</i> , 2010, 23, 595-604.	2.6	7
334	Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy. <i>Leukemia</i> , 2014, 28, 419-422.	7.2	7
335	Preclinical Evidence That ³ Deoxy- ³ [¹⁸ F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy. <i>Cancer Research</i> , 2016, 76, 7089-7095.	0.9	7
336	Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. <i>Haematologica</i> , 2016, 101, 1208-1215.	3.5	7
337	An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 510-519.	7.2	7
338	Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2018, 52, 1701637.	6.7	7
339	Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. <i>Cancers</i> , 2020, 12, 2789.	3.7	7
340	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2095.	3.7	7
341	Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL in Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 335-335.	1.4	7
342	Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 903.	4.1	7

#	ARTICLE	IF	CITATIONS
343	Epigenetic regulation of tumor suppressors in t(8:21)-containing AML. <i>Annals of Hematology</i> , 2004, 83, 329-330.	1.8	6
344	Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia. <i>European Journal of Haematology</i> , 2010, 84, 362-364.	2.2	6
345	POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. <i>Annals of Hematology</i> , 2012, 91, 1419-1425.	1.8	6
346	Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT. <i>European Journal of Haematology</i> , 2016, 97, 232-238.	2.2	6
347	CD7 is expressed on a subset of normal CD34-positive myeloid precursors. <i>European Journal of Haematology</i> , 2018, 101, 318-325.	2.2	6
348	Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. <i>PLoS ONE</i> , 2018, 13, e0200163.	2.5	6
349	Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 13.	6.2	6
350	Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. <i>Leukemia</i> , 2020, 34, 721-734.	7.2	6
351	Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1589-1596.	2.0	6
352	High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience. <i>Annals of Hematology</i> , 2020, 99, 855-866.	1.8	6
353	Comparison of Open-access Databases for Clinical Variant Interpretation in Cancer: A Case Study of MDS/AML. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 157-166.	2.0	6
354	New Molecular Therapy Targets in Acute Myeloid Leukemia. <i>Recent Results in Cancer Research</i> , 2007, 176, 243-262.	1.8	6
355	Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1). <i>Blood</i> , 2018, 132, 4649-4649.	1.4	6
356	Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice. <i>International Journal of Molecular Medicine</i> , 2003, 11, 311-5.	4.0	6
357	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. <i>Biomedicines</i> , 2021, 9, 1842.	3.2	6
358	Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairments. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 264-275.	7.3	6
359	Quantification of cyclin A1 and glyceraldehyde-3-phosphate dehydrogenase expression in testicular biopsies of infertile patients by fluorescence real-time RT-PCR. <i>Journal of Developmental and Physical Disabilities</i> , 2002, 25, 202-209.	3.6	5
360	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017, 99, 544-552.	2.2	5

#	ARTICLE	IF	CITATIONS
361	Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation. <i>BMC Physiology</i> , 2018, 18, 3.	3.6	5
362	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 583-587.	2.5	5
363	The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 30-37.	2.4	5
364	Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD. <i>Blood Cancer Journal</i> , 2021, 11, 42.	6.2	5
365	Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Cancers</i> , 2021, 13, 3439.	3.7	5
366	AL Amyloidosis " Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells. <i>Blood</i> , 2018, 132, 187-187.	1.4	5
367	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. <i>Blood</i> , 2016, 128, 1066-1066.	1.4	5
368	Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	5
369	The onset of active disease in systemic lupus erythematosus patients is characterised by excessive regulatory CD4+T-cell differentiation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 279-288.	0.8	5
370	Solitary plasmacytoma of the lung with coexisting sarcoid-like lesions. <i>Annals of Hematology</i> , 2008, 87, 417-420.	1.8	4
371	Construction and Application of an Inducible System for Homogenous Expression Levels in Bulk Cell Lines. <i>PLoS ONE</i> , 2009, 4, e6445.	2.5	4
372	Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1291396.	0.7	4
373	Successful collection of peripheral blood stem cells upon <i>VIDE</i> chemomobilization in sarcoma patients. <i>European Journal of Haematology</i> , 2017, 99, 459-464.	2.2	4
374	Hematopoietic transcription factors and differential cofactor binding regulate <i>PRKACB</i> isoform expression. <i>Oncotarget</i> , 2017, 8, 71685-71698.	1.8	4
375	<i>IRE1</i> ± maintains HSC stemness under ER-stress. <i>Nature Cell Biology</i> , 2019, 21, 297-298.	10.3	4
376	Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation. <i>Haematologica</i> , 2019, 104, 827-834.	3.5	4
377	AMLVaran: a software approach to implement variant analysis of targeted NGS sequencing data in an oncological care setting. <i>BMC Medical Genomics</i> , 2020, 13, 17.	1.5	4
378	Comments on "Cost of decentralized <i>CAR</i> T cell production in an academic non-profit setting". <i>International Journal of Cancer</i> , 2021, 148, 514-515.	5.1	4

#	ARTICLE	IF	CITATIONS
379	Ruxolitinib is effective in the treatment of a patient with refractory Tâ€ALL. EJHaem, 2021, 2, 139-142.	1.0	4
380	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. Blood, 2018, 132, 720-720.	1.4	4
381	Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial. Blood, 2020, 136, 1-3.	1.4	4
382	Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.. Blood, 2009, 114, 485-485.	1.4	4
383	Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients â‰¥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial. Blood, 2012, 120, 144-144.	1.4	4
384	Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations. Blood, 2016, 128, 453-453.	1.4	4
385	Diagnostic work-up for the detection of malnutrition in hospitalized cancer patients. Journal of Community and Supportive Oncology, 2016, 14, 155-161.	0.1	4
386	The limited contribution of DNA methylation to PML-RAR \pm induced leukemia. Oncotarget, 2013, 4, 5-6.	1.8	4
387	Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL). Blood, 2014, 124, 946-946.	1.4	4
388	Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols. Blood, 2020, 136, 37-38.	1.4	4
389	First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncology Reports, 2005, 14, 1539-42.	2.6	4
390	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood Cancer Journal, 2022, 12, .	6.2	4
391	High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases. Bone Marrow Transplantation, 2012, 47, 1321-1325.	2.4	3
392	A new option for remission induction in acute myeloid leukaemia. Lancet Oncology, The, 2018, 19, 156-157.	10.7	3
393	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemiaâ€™ Letter. Cancer Research, 2018, 78, 6339-6341.	0.9	3
394	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia, 2021, 35, 1521-1526.	7.2	3
395	Abstract 510: Inhibition of IRE1 \pm -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. , 2014, , .		3
396	Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 1461-1461.	1.4	3

#	ARTICLE	IF	CITATIONS
397	Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease. <i>Blood</i> , 2019, 134, 3928-3928.	1.4	3
398	The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells. <i>Blood</i> , 2019, 134, 5620-5620.	1.4	3
399	Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML. <i>Blood</i> , 2013, 122, 597-597.	1.4	3
400	Maintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1. <i>PLoS ONE</i> , 2014, 9, e115578.	2.5	3
401	Epitranscriptomic modifications in acute myeloid leukemia: m ⁶ A and 2â€²-O ⁶ -methylation as targets for novel therapeutic strategies. <i>Biological Chemistry</i> , 2021, 402, 1531-1546.	2.5	3
402	Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma. <i>Blood</i> , 2019, 134, 1783-1783.	1.4	3
403	The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment. <i>Blood</i> , 2021, 138, 729-729.	1.4	3
404	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. <i>Blood</i> , 2021, 138, 4418-4418.	1.4	3
405	Two-Year Evaluation of the German Clinical Amyloidosis Registry. <i>Blood</i> , 2021, 138, 3780-3780.	1.4	3
406	The onset of active disease in systemic lupus erythematosus patients is characterised by excessive regulatory CD4 ⁺ -T-cell differentiation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 279-288.	0.8	3
407	Heparin-Induced Thrombocytopenia vs. Plasmapheresis- Induced Platelet Loss in a Case of Thrombotic Thrombocytopenic Purpura. <i>Transfusion Medicine and Hemotherapy</i> , 2007, 34, 74-77.	1.6	2
408	NPM1 functions in epitranscriptomics. <i>Nature Genetics</i> , 2019, 51, 1436-1437.	21.4	2
409	Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation. <i>Haematologica</i> , 2020, 105, 1454-1464.	3.5	2
410	Phagocytosis by stroma confounds coculture studies. <i>IScience</i> , 2021, 24, 103062.	4.1	2
411	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. <i>Cells</i> , 2021, 10, 152.	4.1	2
412	Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias. <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 173-180.	2.0	2
413	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. <i>Blood</i> , 2019, 134, 2693-2693.	1.4	2
414	Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3363-3363.	1.4	2

#	ARTICLE	IF	CITATIONS
415	Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial. <i>Blood</i> , 2019, 134, 644-644.	1.4	2
416	First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. <i>Oncology Reports</i> , 0, , .	2.6	2
417	The G-CSF Induced MiR-143 Targets MAPK-Family Proteins and Is a Prognostic Factor for RIC-Transplanted AML Patients. <i>Blood</i> , 2014, 124, 2200-2200.	1.4	2
418	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1472-1472.	1.4	2
419	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. <i>Trials</i> , 2021, 22, 765.	1.6	2
420	Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries. <i>Blood</i> , 2021, 138, 872-872.	1.4	2
421	Randomized Phase II Study of All- <i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status. <i>Blood</i> , 2021, 138, 2380-2380.	1.4	2
422	The Bone Marrow Microenvironment of Multiple Myeloma Long-Term Survivors at Single Cell Resolution. <i>Blood</i> , 2020, 136, 32-33.	1.4	2
423	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. <i>Biomedicines</i> , 2022, 10, 373.	3.2	2
424	Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells. <i>International Journal of Oncology</i> , 2003, 23, 151-8.	3.3	2
425	Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice. <i>International Journal of Molecular Medicine</i> , 2003, 11, 311.	4.0	1
426	Alarmins MRP8 and MRP14 Induce Stress Tolerance in Phagocytes under Sterile Inflammatory Conditions. <i>Cell Reports</i> , 2015, 11, 849.	6.4	1
427	Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack. <i>Haematologica</i> , 2018, 103, 1579-1581.	3.5	1
428	Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. <i>Cancers</i> , 2020, 12, 3683.	3.7	1
429	Cryostorage to What End? “ Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 91-98.	1.6	1
430	Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation. <i>British Journal of Haematology</i> , 2021, , .	2.5	1
431	EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1528-1528.	1.4	1
432	Characterization of Patients with Multiple Myeloma in Long- Term Remission. <i>Blood</i> , 2018, 132, 4508-4508.	1.4	1

#	ARTICLE	IF	CITATIONS
433	Profiling of Oncogenic Signaling in Multiple Myeloma – Association with Biology, Disease Progression and Prognosis. <i>Blood</i> , 2018, 132, 3206-3206.	1.4	1
434	DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations. <i>Blood</i> , 2014, 124, 125-125.	1.4	1
435	Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7053-7053.	1.6	1
436	A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis. <i>PLoS ONE</i> , 2015, 10, e0129147.	2.5	1
437	Decitabine and Vitamin D3 Differentially Increase C-Jun, PU.1, and Sp1 Hematopoietic Transcription Factors To Induce Monocytic Differentiation.. <i>Blood</i> , 2006, 108, 2223-2223.	1.4	1
438	Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.. <i>Blood</i> , 2012, 120, 2776-2776.	1.4	1
439	Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3180-3180.	1.4	1
440	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018, 132, 3399-3399.	1.4	1
441	A Severe Case of Anaplastic Large Cell Lymphoma in a Previously Healthy Woman: Diagnostic and Therapeutic Challenges. <i>Prague Medical Report</i> , 2020, 121, 262-266.	0.8	1
442	Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience. <i>Blood</i> , 2021, 138, 3370-3370.	1.4	1
443	Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy. <i>Blood</i> , 2021, 138, 4835-4835.	1.4	1
444	Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial). <i>Blood</i> , 2021, 138, 1734-1734.	1.4	1
445	Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy. <i>Blood</i> , 2021, 138, 3861-3861.	1.4	1
446	Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition. <i>Blood</i> , 2021, 138, 3469-3469.	1.4	1
447	Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning. <i>Blood</i> , 2021, 138, 108-108.	1.4	1
448	The Ribomethylome Landscape of Hematopoietic System. <i>Blood</i> , 2020, 136, 41-42.	1.4	1
449	Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2337.	4.1	1
450	Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD. <i>Frontiers in Oncology</i> , 2022, 12, 862991.	2.8	1

#	ARTICLE	IF	CITATIONS
451	Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 23280.	3.3	1
452	Redirection of Oncoproteins to Kill Cancer Cells. <i>Cell Cycle</i> , 2003, 2, 531-533.	2.6	0
453	In vivo analyses of UV-irradiation-induced p53 promoter binding using a novel quantitative real-time PCR assay. <i>International Journal of Oncology</i> , 2005, 26, 493.	3.3	0
454	The hidden faces of C/EBP β . <i>Blood</i> , 2008, 111, 2949-2950.	1.4	0
455	Prognostic Stratification For Curatively Resected NSCLC Patients By Apoptosis Panel. , 2010, , .		0
456	Mechanism of action of demethylating and immune modulatory agents â€“ Introduction. <i>Cancer Treatment Reviews</i> , 2011, 37, S1.	7.7	0
457	Mechanism of action of demethylating and immune modulatory agents â€“ Conclusion. <i>Cancer Treatment Reviews</i> , 2011, 37, S23-S24.	7.7	0
458	Lats 1 is a putative tumor suppressor in Hoxa9 / Meis induced leukemia. <i>Experimental Hematology</i> , 2013, 41, S20.	0.4	0
459	Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e286-e287.	0.4	0
460	Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution. <i>BMC Cancer</i> , 2020, 20, 353.	2.6	0
461	Distinct Expression Patterns of Human microRNAs in Myeloid Differentiation and Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 2231-2231.	1.4	0
462	Defining the Leukemia Epigenome: Distinct Genome Wide Histone H3 Modification Patterns Exist in AML, ALL and Healthy Hematopoietic Progenitor Cells.. <i>Blood</i> , 2007, 110, 2124-2124.	1.4	0
463	The Cyclin Interactor p26INCA1 Regulates the Hematopoietic Stem Cell Pool Via CDK Inhibition.. <i>Blood</i> , 2007, 110, 637-637.	1.4	0
464	SOCS1 Cooperates with FLT3-ITD In the Development of Myeloproliferative Disease by Promoting the Escape From External Cytokine Control.. <i>Blood</i> , 2010, 116, 1054-1054.	1.4	0
465	Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis. <i>Blood</i> , 2010, 116, 2479-2479.	1.4	0
466	Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts. <i>Blood</i> , 2010, 116, 4184-4184.	1.4	0
467	Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study. <i>Blood</i> , 2010, 116, 2696-2696.	1.4	0
468	Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial. <i>Blood</i> , 2011, 118, 2773-2773.	1.4	0

#	ARTICLE	IF	CITATIONS
469	Histone H3 Methylation Mediates All-Trans-Retinoic Acid Responsiveness in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 224-224.	1.4	0
470	Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis. <i>Blood</i> , 2012, 120, 1974-1974.	1.4	0
471	A Specific DNA Methylation Pattern Is Associated with Delayed Leukemogenesis and Altered Response to Chemotherapeutic Treatment in an Inducible DNMT3b Expressing Mouse Model. <i>Blood</i> , 2012, 120, 398-398.	1.4	0
472	C/EBP β mediates nicotinamide-enhanced clearance of <i>Staphylococcus aureus</i> in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 4301-4301.	8.2	0
473	DNA Methyltransferase 3B (DNMT3B) Protein Expression Predicts Survival in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 1395-1395.	1.4	0
474	Loss Of H3K27 Trimethylation (H3K27me3) Associates With a Multi Drug Resistance Phenotype In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 1253-1253.	1.4	0
475	Identification Of Leukemia Suppressive Genes By Inducible Overexpression Of The DNA Methyltransferase DNMT3B During Leukemogenesis In Mice. <i>Blood</i> , 2013, 122, 2493-2493.	1.4	0
476	In Vivo RNAi Screening Identifies HDAC4 As a Mediator Of Chemoresistance In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1257-1257.	1.4	0
477	Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity. <i>Blood</i> , 2013, 122, 1447-1447.	1.4	0
478	Ubiquitarily Expressed Major Histocompatibility (MHC) Class I and Minor Histocompatibility Alloantigens (mHAg) Are No Relevant Targets For Graft-Versus-Tumor (GvT) Reactions In Mice After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 2013, 122, 3249-3249.	1.4	0
479	The PML/RAR α -Regulated MiR-181a/b-Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. <i>Blood</i> , 2014, 124, 2195-2195.	1.4	0
480	PML-RAR α Repressed MicroRNA 126 Mediates Differentiation in Acute Promyelocytic Leukemia By Targeting the Protooncogene C-Myb. <i>Blood</i> , 2014, 124, 3558-3558.	1.4	0
481	In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response. <i>Blood</i> , 2014, 124, 870-870.	1.4	0
482	Abstract 4430: Loss of the histone methyltransferase EZH2 induces chemoresistance in acute myeloid leukemia (AML). , 2015, , .		0
483	Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years). <i>Blood</i> , 2015, 126, 2025-2025.	1.4	0
484	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling By Suppression of Mir-146a in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1533-1533.	1.4	0
485	High Expression of ARM CX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years). <i>Blood</i> , 2016, 128, 2840-2840.	1.4	0
486	CBF β -SMMHC Inhibition Disrupts Enhancer Chromatin Dynamics and Represses MYC Transcriptional Program in Inv(16) Leukemia. <i>Blood</i> , 2017, 130, 784-784.	1.4	0

#	ARTICLE	IF	CITATIONS
487	Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. Blood, 2018, 132, 4485-4485.	1.4	0
488	Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands. Blood, 2018, 132, 357-357.	1.4	0
489	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion – a Phase I Study (TOL-1). Blood, 2018, 132, 4539-4539.	1.4	0
490	In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylation and Transcriptome Changes in Primary AML Blasts: Random or Specific?. Blood, 2018, 132, 3892-3892.	1.4	0
491	Pre-Conditioning Serum Leptin Levels Predict Early Relapse Rates of High Risk AML after Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 3419-3419.	1.4	0
492	High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 4507-4507.	1.4	0
493	Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction. Blood, 2019, 134, 4487-4487.	1.4	0
494	The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients. Blood, 2019, 134, 873-873.	1.4	0
495	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. Blood, 2019, 134, 3077-3077.	1.4	0
496	Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data. Blood, 2019, 134, 5650-5650.	1.4	0
497	Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma. Blood, 2019, 134, 571-571.	1.4	0
498	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photopheresis Therapy. Blood, 2019, 134, 3287-3287.	1.4	0
499	P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S140-S141.	0.4	0
500	Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders. Blood, 2021, 138, 1579-1579.	1.4	0
501	Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. Blood, 2021, 138, 1307-1307.	1.4	0
502	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). Blood, 2021, 138, 1810-1810.	1.4	0
503	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. Blood, 2020, 136, 10-11.	1.4	0
504	Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype. Blood, 2020, 136, 41-42.	1.4	0

#	ARTICLE	IF	CITATIONS
505	OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S5.	0.4	0
506	P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S65.	0.4	0